Background: Occlusion of retinal veins is a mutual disorder that affect the retina usually occurs when blood clot obstructs a retinal vein.
Aim of the work: To compare the effects of Ranibizumab versus Aflibercept intravitreal injections on macular edema (ME) caused by branch retinal vein occlusion (BRVO).
Patient and Methods: This study was carried out on two groups of patients of either sex with an age ranging from 35 to 70 years. Every patient injected 3 loading doses. Ranibizumab dose is 0.5 mg dose vial (0.05 mL). Aflibercept dose is 2 mg dose vial (0.05 mL). Follow up was done 1st day post operation then monthly for 4 months. The eyes were followed for VA, IOP, OCT, FFA and any complications.
Results: Both groups showed a significant reduction in central macular thickness (CMT) as well as an improvement in best-corrected visual acuity (BCVA). As regard CMT, the reduction and improvement in Aflibercept group was 71.6%, while the reduction and improvement in Ranibizumab group was 61.2%. Regarding to BCVA, the improvement in Aflibercept group was 70.8%, while the improvement in Ranibizumab group was 44.4%. The majority of the patients were satisfied from improvement of vision after injections.
Conclusion: Both Ranibizumab and Aflibercept were efficient drugs in resolving ME secondary to BRVO with a superior improvement in VA and CMT in Aflibercept group compared with basal values.
Key words: Intravitreal injection, Ranibizumab, Aflibercept, macular edema, branch retinal vein occlusion.